

ANALYTICAL STUDY OF SOME ANTIDEPRESSANT AND ANTIPSYCHOTIC DRUGS

THESIS

Presented for the Partial Fulfillment of the Degree of Master in Pharmaceutical Sciences
(Pharmaceutical Analytical Chemistry)

By

Christine Maged Abdou El Maraghy

Department of Pharmaceutical Analytical Chemistry

Faculty of Pharmacy-October University for Modern Sciences & Arts (MSA)

Under supervision of

Prof.Dr. Samia Mahmoud El Gizawy

Professor of Pharmaceutical Analytical Chemistry

Faculty of Pharmacy- Assiut University

Head of Analytical Chemistry Department, MSA University (2006-2010)

Ass.Prof.Dr. Maha Farouk Abd El Ghany

Associate Professor of Pharmaceutical Analytical Chemistry

Faculty of Pharmacy- Ain Shams University

Dr. Omar Abd el-Aziz Ali Ghonim

Lecturer of Pharmaceutical Analytical Chemistry

Faculty of Pharmacy- Ain Shams University

Faculty of Pharmacy

Ain Shams University

2011

TO THE SOUL OF MY FATHER

Acknowledgement

I am deeply thankful to ALLAH by the grace of whom this work was achieved.

*I would like to express my deep gratitude and sincere appreciation to **Prof.Dr. Samia M.ElGizawy**, Professor of Pharmaceutical Analytical chemistry, Faculty of Pharmacy, Assiut University for her faithful support during my work, helpful suggestions and beneficial advice throughout the course of the presented study.*

*I wish to express my deep respect and appreciation to **Ass.Prof. Dr. Maha Farouk Abd El Ghany**, Associate Professor of Pharmaceutical Analytical chemistry, Faculty of Pharmacy, Ain Shams University for her helpful guidance, continuous encouragement during the development of the work and fruitful supervision and continuous support throughout this work.*

*I am deeply endowed with feeling of duty and obligation towards **Dr. Omar Abd el-Aziz A.Ghonim**, Lecturer of Pharmaceutical Analytical chemistry, Faculty of Pharmacy, Ain Shams University for his extensive effort, time and energy invested in supervising my work and preparation of the thesis and for his indispensable advice and encouragement.*

*I would like to thank **Prof.Dr. Nawal El Degwi**, Head of Board of Trustees, and **Dr. Sherif EL-Degwi**, Vice President, MSA University for their helpful support.*

*I would like to thank my **mother** for standing by me in every step of the way and also I want to thank my **sisters** and **brother** for their effective support.*

*Words could never express my deep gratitude to my dear **husband** for standing by me and providing all the advice and support I can ever need.*

Finally, I would like to extend my deep thanks to all my colleagues of the Pharmaceutical Analytical chemistry Department, October for Modern sciences & Arts (MSA) University.

CONTENTS

Par I: General Introduction

	Page
I. General introduction	1

Part II: Literature Review

II.1.Methods of Analysis of Citalopram Hydrobromide.	15
II.1.1.Spectroscopic Methods	15
II.1.1.1.Colorimetric Method	15
II.1.1.2.Spectrophotometric Methods	15
II.1.1.3.Spectrofluorimetric Methods	15
II.1.2.Electroanalytical Methods(Voltammetric Method)	16
II.1.3.Capillary Electrophoresis (CE)	16
II.1.4.Chromatographic Methods	17
II.1.4.1.Thin Layer Chromatography (TLC)	17
II.1.4.2. High Performance Liquid Chromatography (HPLC)	19
II.1.4.3. Gas Chromatography (GC)	22
II.2. Methods of Analysis of Aripiprazole	23
II.2.1. Spectroscopic Methods	23
II.2.1.1. Spectrophotometric Methods	23
II.2.2.Capillary Electrophoresis (CE)	23
II.2.3.Chromatographic Methods	24
II.2.3.1. High Performance Liquid Chromatography (HPLC)	24
II.2.1.2. Gas Chromatography (GC)	25
II.3. Methods of Analysis of Quetiapine Fumarate	26

II.3.1. Titrimetric Method	26
II.3.2. Spectroscopic Methods	26
II.3.2.1. Colorimetric Method	26
II.3.2.2. Spectrophotometric Methods	26
II.3.3. Electroanalytical Methods	27
II.3.3.1. Potentiometric Method	27
II.3.3.2. Voltammetric Methods	27
II.3.4. Capillary Electrophoresis (CE)	28
II.3.5. Chromatographic Methods	28
II.3.5.1. Thin Layer Chromatography (TLC)	28
II.3.5.2. High Performance Liquid Chromatography (HPLC)	29
II.3.5.3. Gas Chromatography (GC)	32

Part III:

Stability- Indicating Spectrophotometric Methods, Using Derivative Technique

Introduction	33
--------------	----

Section A

Stability- Indicating Spectrophotometric Methods for Determination of Citalopram Hydrobromide in Presence of Its Degradates, Using Derivative Technique

III.A.1. Experimental	35
III.A.1.1. Instrumentation	35
III.A.1.2. Samples and Reagent	36
III.A.1.2.1. Authentic Sample	36
III.A.1.2.2. Market Pharmaceutical Preparation	36
III.A.1.2.3. Chemicals and Reagents	36
III.A.1.3. Standard Solutions	37
III.A.1.3.A. Standard Solution of Citalopram Hydrobromide (100.00 µgml ⁻¹)	37

III.A.1.3.B. Preparation of Citalopram Hydrobromide Degradates	37
III.A.1.3.B.1. Alkaline-degrade Solution ($100.00\mu\text{gml}^{-1}$)	37
III.A.1.3.B.2. Oxidative-degrade Solution ($100.00\mu\text{gml}^{-1}$)	37
III.A.1.4. Procedure	38
III.A.1.4.1. Scanning of the Absorption Spectra of Citalopram Hydrobromide, its Alkaline and Oxidative-degradates	38
III.A.1.4.2. Method Validation	38
III.A.1.4.2.1. Linearity	38
III.A.1.4.2.1.1. First Derivative Spectrophotometric Method	38
III.A.1.4.2.1.2. Second Derivative Spectrophotometric Method	39
III.A.1.4.2.1.3. Third Derivative Spectrophotometric Method	39
III.A.1.4.2.2. Accuracy	39
III.A.1.4.2.3. Precision	40
III.A.1.4.2.3.a. Repeatability	40
III.A.1.4.2.3.b. Intermediate Precision	40
III.A.1.4.2.4. Selectivity	40
III.A.1.4.3. Application to the Pharmaceutical Preparation	40
III.A.1.4.4. Validation by Standard Addition Technique	41
III.A.2. Results and Discussion	42
III.A.3. Conclusion	68

Section B

Stability- Indicating Spectrophotometric Methods for Determination of Aripiprazole in Presence of Its Degradates, Using Derivative Technique	
III.B.1. Experimental	69
III.B.1.1. Instrumentation	69
III.B.1.2. Samples and Reagents	69
III.B.1.2.1. Authentic Sample	69

III.B.1.2.2. Market Pharmaceutical Preparation	69
III.B.1.2.3. Chemicals and Reagents	69
III.B.1.3. Standard Solutions	70
III.B.1.3.A. Standard Solution of Aripiprazole ($100.00\mu\text{gml}^{-1}$)	70
III.B.1.3.B. Preparation of Aripiprazole Degradates	70
III.B.1.3.B.1. Alkaline-degrade Solution ($100.00\mu\text{gml}^{-1}$)	70
III.B.1.3.B.2. Oxidative-degrade Solution ($100.00\mu\text{gml}^{-1}$)	70
III.B.1.4. Procedure	71
III.B.1.4.1. Scanning of the Absorption Spectra of Aripiprazole, its Alkaline and Oxidative-degradates	71
III.B.1.4.2. Method Validation	71
III.B.1.4.2.1. Linearity	71
III.B.1.4.2.1.1. Second Derivative Spectrophotometric Method	71
III.B.1.4.2.1.2. Third Derivative Spectrophotometric Method	72
III.B.1.4.2.2. Accuracy	72
III.B.1.4.2.3. Precision	72
III.B.1.4.2.3.a. Repeatability	72
III.B.1.4.2.3.b. Intermediate Precision	73
III.B.1.4.2.4. Selectivity	73
III.B.1.4.3. Application to the Pharmaceutical Preparation	73
III.B.1.4.4. Validation by Standard Addition Technique	73
III.B.2. Results and Discussion	75
III.B.3. Conclusion	98

Part IV

Stability- Indicating Spectrophotometric Methods, Using Derivative Ratio Technique

Introduction	99
--------------	----

Section A

**Stability- Indicating Spectrophotometric Methods for Determination of
Citalopram Hydrobromide in Presence of Its Degradates, Using
Derivative Ratio Technique**

IV.A.1. Experimental	101
IV.A.1.1. Instrumentation	101
IV.A.1.2. Samples and Reagents	101
IV.A.1.2.1. Authentic Sample	101
IV.A.1.2.2. Market Pharmaceutical Preparation	101
IV.A.1.2.3. Chemicals and Reagents	101
IV.A.1.3. Standard Solutions	102
IV.A.1.3.A. Standard Solution of Citalopram Hydrobromide ($100.00\mu\text{gml}^{-1}$)	102
IV.A.1.3.B. Preparation of Citalopram Hydrobromide Degradates	102
IV.A.1.3.B.1. Alkaline-degradate solution ($100.00\mu\text{gml}^{-1}$)	102
IV.A.1.3.B.2. Oxidative-degradate solution ($100.00\mu\text{gml}^{-1}$)	102
IV.A.1.4. Procedure	102
IV.A.1.4.1. Scanning of the absorption spectra of Citalopram Hydrobromide, its Alkaline and Oxidative-degradates	102
IV.A.1.4.2. Method Validation	103
IV.A.1.4.2.1. Linearity	103
IV.A.1.4.2.2. Accuracy	103
IV.A.1.4.2.3. Precision	104
IV.A.1.4.2.3.a. Repeatability	104
IV.A.1.4.2.3.b. Intermediate Precision	104
IV.A.1.4.2.4. Selectivity	104
IV.A.1.4.3. Application to the Pharmaceutical Preparation	105
IV.A.1.4.4. Validation by Standard Addition Technique	105
IV.A.2. Results and Discussion	106
IV.A.3. Conclusion	121

Section B

Stability- Indicating Spectrophotometric Methods for Determination of Aripiprazole in Presence of Its Degradates, Using Derivative Ratio Technique

IV.B.1. Experimental	122
IV.B.1.1. Instrumentation	122
IV.B.1.2. Samples and Reagents	122
IV.B.1.2.1. Authentic Sample	122
IV.B.1.2.2. Market Pharmaceutical Preparation	122
IV.B.1.2.3. Chemicals and Reagents	122
IV.B.1.3 Standard Solutions	122
IV.B.1.3.A. Standard Solution of Aripiprazole	122
IV.B.1.3.B. Preparation of Aripiprazole Degradates	122
IV.B.1.3.B.1. Alkaline-degrade Solution ($100.00\mu\text{gml}^{-1}$)	122
IV.B.1.3.B.2. Oxidative-degrade Solution ($100.00\mu\text{gml}^{-1}$)	123
IV.B.1.4. Procedure	123
IV.B.1.4.1. Scanning of the Absorption Spectra of Aripiprazole , its Alkaline and Oxidative-degradates	123
IV.B.1.4.2. Method Validation	123
IV.B.1.4.2.1. Linearity	123
IV.B.1.4.2.2. Accuracy	124
IV.B.1.4.2.3. Precision	124
IV.B.1.4.2.3.a. Repeatability	124
IV.B.1.4.2.3.b. Intermediate Precision	124
IV.B.1.4.2.4. Selectivity	125
IV.B.1.4.3. Application to the Pharmaceutical Preparation	125
IV.B.1.4.4. Validation by Standard Addition Technique	125
IV.B.2. Results and Discussion	126

IV.B.3. Conclusion	140
--------------------	-----

Section C

Stability- Indicating Spectrophotometric Methods for Determination of Quetiapine Fumarate in Presence of Its Impurities, Using Derivative Ratio Technique

IV.C.1. Experimental	141
IV.C.1.1. Instrumentation	141
IV.C.1.2. Samples and Reagents	141
IV.C.1.2.1. Authentic Sample	141
IV.C.1.2.2. Market Pharmaceutical Preparation	141
IV.C.1.2.3. Chemicals and Reagents	142
IV.C.1.3. Standard Solutions	142
IV.C.1.3.1. Standard Solution of Quetiapine Fumarate ($100.00\mu\text{gml}^{-1}$)	142
IV.C.1.3.2. Standard Solutions of Quetiapine Impurities	142
IV.C.1.3.2.A. Standard Solution of Quetiapine N-oxide ($100.00\mu\text{gml}^{-1}$)	142
IV.C.1.3.2.B. Standard Solution of Desethanol Quetiapine ($100.00\mu\text{gml}^{-1}$)	142
IV.C.1.4. Procedure	143
IV.C.1.4.1. Scanning of the Absorption Spectra of Quetiapine Fumarate and its Two Impurities; Quetiapine N-oxide and Desethanol Quetiapine	143
IV.C.1.4.2. Method Validation	143
IV.C.1.4.2.1. Linearity	143
IV.C.1.4.2.2. Accuracy	144
IV.C.1.4.2.3. Precision	144
IV.C.1.4.2.3.a. Repeatability	144
IV.C.1.4.2.3.b. Intermediate Precision	144
IV.C.1.4.2.4. Selectivity	144
IV.C.1.4.3. Application to the Pharmaceutical Preparation	145

IV.C.1.4.4. Validation by Standard Addition Technique	145
IV.C.2. Results and Discussion	146
IV.C.3. Conclusion	159

Part V

Stability- Indicating Spectrophotometric Methods, Using pH-Induced Difference Technique

Introduction	160
--------------	-----

Section A

Stability- Indicating Spectrophotometric Methods for Determination of Citalopam Hydrobromide in Presence of Its Alkaline-Degradate, Using pH-Induced Difference Technique

V.A.1. Experimental	161
V.A.1.1. Instrumentation	161
V.A.1.2. Samples and Reagents	161
V.A.1.2.1. Authentic Sample	161
V.A.1.2.2. Market Pharmaceutical Preparation	161
V.A.1.2.3. Chemicals and Reagents	161
V.A.1.3. Standard Solutions	162
V.A.1.3.A. Standard Solution of Citalopram Hydrobromide($100.00\mu\text{gml}^{-1}$)	162
V.A.1.3.B. Preparation of Citalopram Hydrobromide Degradate	162
V.A.1.4.B.1. Alkaline-degradate Solution ($100.00\mu\text{gml}^{-1}$)	162
V.A.1.4. Procedure	162
V.A.1.4.1. Scanning of the Absorption Spectra of Citalopram Hydrobromide and its Alkaline-degradate	162
V.A.1.4.2. Method Validation	162
V.A.1.4.2.1. Linearity	162
V.A.1.4.2.2. Accuracy	163
V.A.1.4.2.3. Precision	163
V.A.1.4.2.3.a. Repeatability	163

V.A.1.4.2.3.b. Intermediate Precision	164
V.A.1.4.2.4. Selectivity	164
V.A.1.4.3. Application to the Pharmaceutical Preparation	164
V.A.1.4.4. Validation by Standard Addition Technique	164
V.A.2. Results and Discussion	166
V.A.3. Conclusion	176

Section B

Stability- Indicating Spectrophotometric Methods for Determination of Aripiprazole in Presence of Its Alkaline-Degradate, Using pH-Induced Difference Technique

V.B.1. Experimental	177
V.B.1.1. Instrumentation	177
V.B.1.2. Samples and Reagents	177
V.B.1.2.1. Authentic Sample	177
V.B.1.2.2. Market Pharmaceutical Preparation	177
V.B.1.2.3. Chemicals and Reagents	177
V.B.1.3. Standard Solutions	177
V.B.1.3.A. Standard Solution of Aripiprazole (100.00 μgml^{-1})	177
V.B.1.3.B. Preparation of Aripiprazole Degradate	178
V.B.13.B.1. Alkaline-degradate Solution (100.00 μgml^{-1})	178
V.B.1.4. Procedure	178
V.B.1.4.1. Scanning of the Absorption Spectra of Aripiprazole and its Alkaline-degradate	178
V.B.1.4.2. Method Validation	178
V.B.1.4.2.1. Linearity	178
V.B.1.4.2.2. Accuracy	179
V.B.1.4.2.3. Precision	179
V.B.1.4.2.3.a. Repeatability	179

V.B.1.4.2.3.b. Intermediate Precision	179
V.B.1.4.2.4. Selectivity	179
V.B.1.4.3. Application to the Pharmaceutical Preparation	180
V.B.1.4.4. Validation by Standard Addition Technique	180
V.B.2. Results and Discussion	181
V.B.3. Conclusion	191

Part VI

Stability-Indicating Methods, Using High Performance Liquid Chromatographic Technique

Introduction	192
--------------	-----

Section A

Stability- Indicating Methods for Determination of Citalopam Hydrobromide in Presence of Its Degradates, Using High Performance Liquid Chromatographic Technique

VI.A.1. Experimental	194
VI.A.1.1. Instrumentation	194
VI.A.1.2. Samples and Reagents	195
VI.A.1.2.1. Authentic Sample	195
VI.A.1.2.2. Market Pharmaceutical Preparation	195
VI.A.1.2.3. Chemicals and Reagents	195
VI.A.1.3. Standard Solutions	195
VI.A.1.3.A. Standard Solution of Citalopram Hydrobromide ($100.00\mu\text{gml}^{-1}$)	195
VI.A.1.3.B. Preparation of Citalopram Hydrobromide Degradates	196
VI.A.1.3.B.1. Alkaline-degradate Solution ($100.00\mu\text{gml}^{-1}$)	196
VI.A.1.3.B.2. Oxidative-degradate Solution ($100.00\mu\text{gml}^{-1}$)	196
VI.A.1.4. Procedure	196
VI.A.1.4.1. Chromatographic Conditions	196
VI.A.1.4.2. Method Validation	196

VI.A.1.4.2.1. Linearity	196
VI.A.1.4.2.2. Accuracy	197
VI.A.1.4.2.3. Precision	197
VI.A.1.4.2.3.a. Repeatability	197
VI.A.1.4.2.3.b. Intermediate Precision	197
VI.A.1.4.2.4. Selectivity	198
VI.A.1.4.3. Application to the Pharmaceutical Preparation	198
VI.A.1.4.4. Validation by Standard Addition Technique	198
VI.A.1.4.5. Application to Spiked Human Plasma	199
VI.A.2. Results and Discussion	200
VI.A.3. Conclusion	220

Section B

Stability- Indicating Methods for Determination of Aripiprazole in Presence of Its Degradates, Using High Performance Liquid Chromatographic Technique

VI.B.1. Experimental	221
VI.B.1.1. Instrumentation	221
VI.B.1.2. Samples and Reagents	221
VI.B.1.2.1. Authentic Sample	221
VI.B.1.2. 2. Market Pharmaceutical Preparation	221
VI.B.1.2.3. Chemicals and Reagents	221
VI.B.1.3. Standard Solutions	221
VI.B.1.3.A. Standard Solution of Aripiprazole($100.00\mu\text{gml}^{-1}$)	221
VI.B.1.3.B. Preparation of Aripiprazole Degradates	221
VI.B.1.3.B.1. Alkaline-degradate Solution ($100.00\mu\text{gml}^{-1}$)	221
VI.B.1.3.B.2. Oxidative-degradate Solution ($100.00\mu\text{gml}^{-1}$)	222

VI.B.1.4. Procedure	222
VI.B.1.4.1. Chromatographic Conditions	222
VI.B.1.4.2. Method Validation	222
VI.B.1.4.2.1. Linearity	222
VI.B.1.4.2.2. Accuracy	223
VI.B.1.4.2.3. Precision	223
VI.B.1.4.2.3.a. Repeatability	223
VI.B.1.4.2.3.b. Intermediate Precision	223
VI.B.1.4.2.4. Selectivity	223
VI.B.1.4.3. Application to the Pharmaceutical Preparation	224
VI.B.1.4.4. Validation by Standard Addition Technique	224
VI.B.1.4.5. Application to Spiked Human Plasma	224
VI.B.2. Results and Discussion	226
VI.B.3. Conclusion	246

Section C

Stability- Indicating Methods for Determination of Quetiapine Fumarate in Presence of Its Impurities, Using High Performance Liquid Chromatographic Technique

VI.C.1. Experimental	247
VI.C.1.1. Instrumentation	247
VI.C.1.2. Samples and Reagents	247
VI.C.1.2.1. Authentic Sample	247
VI.C.1.2.2. Market Pharmaceutical Preparation	247
VI.C.1.2.3. Chemicals and Reagents	248
VI.C.1.3. Standard Solutions	248
VI.C.1.3.1. Standard Solution of Quetiapine Fumarate	248
IV.C.1.3.2. Standard Solutions of Quetiapine Impurities	248
VI.C.1.3.2.A. Standard Solution of Quetiapine N-oxide	248